Skip to main content
See every side of every news story
Published • loading... • Updated

Harbour BioMed Announces NMPA Acceptance of IND Application for Its First AI-Enabled Drug Candidate LET003 for the Treatment of Overweight or Obesity

  • China’s National Medical Products Administration accepted Harbour BioMed’s IND application for LET003, the company’s first AI-enabled drug candidate for overweight or obesity treatment.
  • LET003 is a dual ACVR2A/ACVR2B-blocking monoclonal antibody developed using Harbour BioMed’s Hu-mAtrIx™ AI platform.
  • In preclinical studies, Harbour BioMed reported that LET003 showed better pharmacokinetic characteristics than several competitor molecules.
  • Harbour BioMed reported that LET003 enhanced fat reduction when combined with semaglutide while preserving lean mass, and that a lower dose promoted lean mass similarly to a higher dose of bimagrumab.
Insights by Ground AI

17 Articles

Williamson HeraldWilliamson Herald
+16 Reposted by 16 other sources
Center

Harbour BioMed Announces NMPA Acceptance of IND Application for Its First AI-Enabled Drug Candidate LET003 for the Treatment of Overweight or Obesity

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI , Nov. 18, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 74% of the sources are Center
74% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Clayton News broke the news in Clayton, United States on Thursday, November 19, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal